Skip to main content
L&C BIO Co., Ltd logo

L&C BIO Co., Ltd — Investor Relations & Filings

Ticker · 290650 ISIN · KR7290650001 KO Manufacturing
Open in API
Filings indexed 378 across all filing types
Latest filing 2022-06-14 Regulatory Filings
Country KR South Korea
Listing KO 290650

About L&C BIO Co., Ltd

http://www.lncbio.co.kr/?locale=en_US

L&C BIO Co., Ltd. is a biotechnology company specializing in regenerative medicine. The company develops, manufactures, and commercializes human tissue-based medical devices and allograft treatment materials. Its core operations include the processing, storage, and distribution of human tissues, with a focus on skin, musculoskeletal, and soft tissues, utilizing patented processing technologies. The company's product portfolio also extends to other medical devices and cosmetics. L&C BIO supports its activities through dedicated research and development centers and manufacturing facilities, including a human tissue plant and a pharmaceutical plant, to advance its pipeline and serve global markets.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(무릎 연골 관절염 치료재 MegaCarti®(메가카티®) 품목허가(NDA) 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KIND) titled 'Investment Judgment Related Major Management Matters'. It details the submission of a New Drug Application (NDA) for a medical device (MegaCarti) to the Ministry of Food and Drug Safety (MFDS). Since this is a specific regulatory announcement regarding a material business event (product approval application) and does not fit into categories like financial reports, M&A, or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2022-06-14 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (Corporate Day). It provides details such as the date, location, purpose, and agenda for the meeting. Since it is an announcement of an event rather than the presentation slides themselves, and it does not fit into the specific report categories, it is classified as a Regulatory Filing (RNS) as it serves as a general corporate disclosure.
2022-05-31 Korean
타법인주식및출자증권취득결정
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory disclosure from L&C Bio regarding the acquisition of shares in another company (Curexo). It details the acquisition amount, purpose, and financial impact, which constitutes a corporate transaction or M&A-related activity. Since it does not fit into the specific categories of 'M&A Activity' (which usually implies a merger or takeover bid) or other specific categories, and it is a standard regulatory filing for a material corporate event, it is best classified as a Regulatory Filing (RNS).
2022-05-23 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, time, location, purpose, and the agenda for the conference call. Since this is an announcement of an event rather than the presentation slides themselves or a transcript, it falls under the category of a regulatory filing announcing an event or report publication.
2022-05-20 Korean
투자판단관련주요경영사항(무릎 연골 관절염 치료재 MegaCarti®(메가카티®) 임상시험(Topline data) 결과)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (L&C Bio) submitted to the KRX (Korea Exchange) regarding 'Major Management Matters' (투자판단 관련 주요경영사항). It details the results of a clinical trial (Topline data) for a medical device. Since this is a specific regulatory disclosure regarding material business developments (clinical trial results) that does not fit into categories like financial reports, dividends, or M&A, it is classified as a Regulatory Filing (RNS).
2022-05-19 Korean
분기보고서 (2022.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for L&C BIO Co., Ltd. for the first quarter of 2022 (12th fiscal year). It contains detailed financial data, business operations, management discussions, and capital structure information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-05-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.